A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
Clinical trial NCT00002155 · COMPLETED
Trial details
- NCT number
- NCT00002155
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.